Effect of inhaled corticosteroids on glycemic status

Open Respiratory Medicine Journal

Volumn 8, Issue , 2014, Pages 101-105

  Egbuonu, Francis ^a   Antonio, Farrah A ^a   Edavalath, Mahamood ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Diabetes control; Diabetes mellitus; Dysglycemic status; Hyperglycemia; Inhaled corticosteroids (ICS); Steroidinduced diabetes

Indexed keywords

FATTY ACID; FLUTICASONE; GLUCOCORTICOID; HEMOGLOBIN A1C; TRIACYLGLYCEROL; TRIAMCINOLONE;

ADRENAL SUPPRESSION; ARTICLE; ASTHMA; BONE DENSITY; BONE NECROSIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CUSHING SYNDROME; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DYSGLYCEMIA; EDEMA; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAOCULAR HYPERTENSION; MOON FACE; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSTRUCTIVE AIRWAY DISEASE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84928892189     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401408010101     Document Type: Article

References (47)

1. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
2. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13-6.
3. De Coster DA, Jones M. Tailoring of corticosteroids in COPD management. Curr Respir Care Rep 2014; 3: 121-32.
4. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012; 106: 989-97
5. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-84.
6. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132
7. Martinez-Ceron E, Barquiel B, Pallardo LF, Alvarez-Sala R. Chronic Obstructive Pulmonary Disease and Diabetes Mellitus. In: Kian-Chung Ong, Ed.. Chronic Obstructive Pulmonary Disease-Current Concepts and Practice (2012). Available from: http://www.intechopen.com/books/chronic-obstructive-pulmonarydisease-current-concepts-and-practice/chronic-obstructivepulmonary-disease-and-diabetes-mellitus [Accessed on 29 May 2014].
8. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 513-23.
9. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997; 99: 414-23.
10. Kahn SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
11. Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 1980; 50: 495-501.
12. Kalhan SC, Adam PA. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J Clin Endocrinol Metab 1975; 41: 600-10.
13. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
14. Defronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-7.
15. Long W, Barrett EJ, Wei L, Liu Z. Adrenalectomy enhances the insulin sensitivity of muscle protein synthesis. Am J Physiol Endocrinol Metab 2003; 284: E102-9.
16. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005; 48: 2119-30.
17. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998; 47: 3-6.
18. Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acidinduced skeletal muscle insulin resistance in humans. Diabetes 2002; 51: 599-605.
19. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003; 27(Suppl. 3): S6-11.
20. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(Suppl 3): 14-23.
21. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007; 275: 43-61.
22. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 1984; 64: 170-259.
23. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-207.
24. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-64.
25. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011; 78: 748-56.
26. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007; 105: c54-7.
27. Bevier WC, Zisser HC, Jovanovic L, et al. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. J Diabetes Sci Technol 2008; 2: 578-83.
28. Cagdas DN, Paç FA, Cakal E. Glucocorticoid-induced diabetic ketoacidosis in acute rheumatic fever. J Cardiovasc Pharmacol Ther 2008; 13: 298-300.
29. Yang JY, Cui XL, He XJ. Non-ketotic hyperosmolar coma complicating steroid treatment in childhood nephrosis. Pediatr Nephrol 1995; 9: 621-22.
30. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-96.
31. Davidson J, Wilkinson A, Dantal J, et al. International Expert Panel. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75(Suppl 10): SS3-24.
32. World Health Organization. Chronic respiratory diseases 2011. Geneva: World Health Organization. http://www.who.int/respira tory/about_topic/en/ Accessed on 02 June 2014.
33. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112(3 Suppl): S1-40.
34. Pedersen S, O'Byrne PM. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(Suppl 39): 1-34.
35. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
36. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007; 20: 23-35.
37. Faul JL, Tormey W, Tormey V, Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ 1998; 317(7171): 1491.
38. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009; 122: 472-8.
39. Faul JL, Wilson SR, Chu JW, Canfield J, Kuschner WG. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 2009; 7: 14-20.
40. O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012; 106: 1487-93.
41. Kiviranta K, Turpeinen M. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax 1993; 48: 974-8.
42. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-6.
43. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132.
44. Yun HD, Knoebel E, Fenta Y, et al. Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. Mayo Clin Proc 2012; 87: 953-60.
45. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-9.
46. Black MH, Anderson A, Bell RA, et al. Prevalence of asthma and its association with glycemic control among youth with diabetes. Pediatrics 2011; 128: e839-47.
47. Bevier WC, Zisser HC, Jovanovic L, et al. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. J Diabetes Sci Technol 2008; 2: 578-83.